Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 3:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 18,392 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Female Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Does the Use of Continuous Glucose Monitoring (CGM) in the Immediate Postpartum Period in Women With Pregestational Diabetes Admitted to the Hospital Decrease Hypoglycemic Episodes

NCT06141941
View directory record Official record
Conditions
Pregestational Diabetes
Interventions
CGM
Device
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 21, 2026, 3:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Does a Mainstream Summer Camp Experience Improve Pediatric Kidney Patients' Physical Fitness and Self Concept?

NCT02803541
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
12 day mainstream summer camp experience
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
8 Years to 17 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Claryville, New York
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Oct 21, 2026, 3:14 PM EDT
Recruiting Phase 1Phase 2 Interventional

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

NCT05000294
View directory record Official record
Conditions
Bile Duct Cancer, Gall Bladder Cancer, Breast Cancer, Neuroendocrine Tumors, Ovarian Cancer, Pancreatic Adenocarcinoma, Soft Tissue Sarcoma, Vulvar Cancer, Prostate Cancer
Interventions
Atezolizumab, Tivozanib
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 21, 2026, 3:14 PM EDT
Completed Not applicable Interventional

Blueberries for Improving Vascular Endothelial Function in Postmenopausal Women With Elevated Blood Pressure

NCT03370991
View directory record Official record
Conditions
Menopause, Elevated Blood Pressure, Hypertension, Endothelial Dysfunction
Interventions
Blueberry Powder, Placebo Powder
Dietary Supplement
Lead sponsor
Colorado State University
Other
Eligibility
45 Years to 65 Years · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 14, 2022 · Synced Oct 21, 2026, 3:14 PM EDT
Recruiting Phase 4 Interventional Results available

Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response

NCT03096418
View directory record Official record
Conditions
Breast Neoplasm Female
Interventions
Paclitaxel
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
2
States / cities
Iowa City, Iowa • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 21, 2026, 3:14 PM EDT
Completed No phase listed Observational

Automated urIne Flow Detection to Reduce Errors and Nursing Workload

NCT03636113
View directory record Official record
Conditions
Acute Kidney Injury, Kidney Injury
Interventions
Clarity RMS Electronic Sensor
Device
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Oct 21, 2026, 3:14 PM EDT
Completed Not applicable Interventional Results available

Effect of Caloric Restriction on Fat Oxidation in Obese Men and Women (Magellan II)

NCT01616082
View directory record Official record
Conditions
Obesity, Overweight, Metabolic Diseases
Interventions
Low Calorie Diet (LCD), Phentermine
Behavioral · Drug
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Nov 13, 2020 · Synced Oct 21, 2026, 3:14 PM EDT
Completed Not applicable Interventional

Transcutaneous Tibial Nerve Stimulation for Spinal Cord Injury Neurogenic Bladder

NCT04350359
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Variable-dose TTNS Protocol 5 x week, Fixed-dose TTNS Protocol, Variable-dose TTNS Protocol 2 x week
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 75 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 21, 2026, 3:14 PM EDT
Not listed Not applicable Interventional

Healthy ME: Advancing Health Equity in Lymphatic Pain and Lymphedema in Black and Hispanic Women With Breast Cancer

NCT06133959
View directory record Official record
Conditions
Breast Cancer
Interventions
The-Optimal-Lymph-Flow (TOLF) Program
Behavioral
Lead sponsor
University of Missouri, Kansas City
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Oct 21, 2026, 3:14 PM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2

NCT01593020
View directory record Official record
Conditions
Breast Cancer
Interventions
Paclitaxel, Eribulin, 5-Fluorouracil, Epirubicin, Cyclophosphamide, Doxorubicin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Oct 21, 2026, 3:14 PM EDT
Completed No phase listed Observational

Comparative Outcome Measures of Patients Receiving Acute Renal ThErapy Study

NCT04912024
View directory record Official record
Conditions
End Stage Kidney Disease, End Stage Renal Disease, Acute Kidney Injury
Interventions
Intermittent Renal Replacement Therapy using the Tablo Hemodialysis System, Intermittent Renal Replacement Therapy using Conventional Hemodialysis Systems
Device
Lead sponsor
Outset Medical
Industry
Eligibility
18 Years and older
Enrollment
458 participants
Timeline
2021 – 2022
U.S. locations
2
States / cities
Orlando, Florida • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2022 · Synced Oct 21, 2026, 3:14 PM EDT
Recruiting Phase 1Phase 2 Interventional

Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON Trial

NCT06866262
View directory record Official record
Conditions
Locally Advanced Clear Cell Renal Cell Carcinoma, Locally Advanced Sarcomatoid Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Inulin, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Questionnaire Administration
Procedure · Dietary Supplement · Biological + 1 more
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 21, 2026, 3:14 PM EDT
Completed Phase 3 Interventional Results available

Multi-Center Study of New Medications to Treat Vaginal Infections

NCT02308046
View directory record Official record
Conditions
Vaginal Infection
Interventions
Terconazole, Placebo
Drug
Lead sponsor
Curatek Pharmaceuticals, LLC
Industry
Eligibility
12 Years and older · Female only
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
41
States / cities
Birmingham, Alabama • Chandler, Arizona • Scottsdale, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Oct 21, 2026, 3:14 PM EDT
Completed Phase 1 Interventional

A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

NCT05375903
View directory record Official record
Conditions
Non-muscle Invasive Bladder Cancer, NMIBC, Carcinoma in Situ of Bladder, Bladder Cancer, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent
Interventions
UGN-301, UGN-201, Gemcitabine
Drug
Lead sponsor
UroGen Pharma Ltd.
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
7
States / cities
Little Rock, Arkansas • Los Angeles, California • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 21, 2026, 3:14 PM EDT
Withdrawn Phase 3 Interventional

Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)

NCT04943627
View directory record Official record
Conditions
Advanced Cancer, Metastatic Cervical Cancer
Interventions
Balstilimab (BAL), Topotecan, Vinorelbine, Gemcitabine, Irinotecan, Pemetrexed
Drug
Lead sponsor
Agenus Inc.
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Oct 21, 2026, 3:14 PM EDT
Completed No phase listed Observational

Factors Associated With Mortality in Neonates

NCT01215461
View directory record Official record
Conditions
Neonatal Mortality
Interventions
Not listed
Lead sponsor
Pediatrix
Other
Eligibility
22 Weeks to 44 Weeks
Enrollment
645 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Anchorage, Alaska
Source: ClinicalTrials.gov public record
Updated May 14, 2013 · Synced Oct 21, 2026, 3:14 PM EDT
Completed Phase 3 Interventional

Behavior Therapy for Children and Adolescents With Obsessive-Compulsive Disorder (OCD)

NCT00000386
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Exposure and Response Prevention, Family Treatment Program, Relaxation Training, Behavior therapy, Family Counseling
Behavioral
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
8 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 12, 2008 · Synced Oct 21, 2026, 3:14 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

NCT05789069
View directory record Official record
Conditions
Renal Cell Carcinoma, Melanoma, Non Small Cell Lung Cancer, Gastric Cancer, Colorectal Cancer
Interventions
HFB200603, Tislelizumab
Drug
Lead sponsor
HiFiBiO Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Los Angeles, California • Philadelphia, Pennsylvania • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 21, 2026, 3:14 PM EDT
Completed Early Phase 1 Interventional

Pilot Study of Denileukin Diftitox Plus High-Dose IL-2 for Patients With Metastatic Renal Cancer

NCT00278369
View directory record Official record
Conditions
Kidney Cancer
Interventions
aldesleukin, denileukin diftitox
Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 22, 2013 · Synced Oct 21, 2026, 3:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Open-Label, Within-Subject Dose-Escalation Study to Evaluate the Clinical Safety and Pharmacokinetic Profile of a Topical Sildenafil Cream (5% w/w), in Healthy Postmenopausal Women

NCT02364882
View directory record Official record
Conditions
Female Sexual Health
Interventions
Sildenafil
Drug
Lead sponsor
Strategic Science & Technologies, LLC
Industry
Eligibility
35 Years to 65 Years · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 22, 2015 · Synced Oct 21, 2026, 3:14 PM EDT
Completed Not applicable Interventional

Telephone Support Intervention to Improve Breastfeeding

NCT00717496
View directory record Official record
Conditions
Breastfeeding
Interventions
Telephone Support Intervention to Improve Breastfeeding
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older · Female only
Enrollment
339 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 8, 2013 · Synced Oct 21, 2026, 3:14 PM EDT
Completed Not applicable Interventional Results available

Women Veterans' Substance Abuse Treatment

NCT00734903
View directory record Official record
Conditions
Substance Use Disorders
Interventions
A Woman's Path to Recovery, 12-Step Facilitation
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years · Female only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Bedford, Massachusetts • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 5, 2018 · Synced Oct 21, 2026, 3:14 PM EDT
Completed Phase 2 Interventional

Phase IIa Trial to Determine the Effects of Bardoxolone Methyl on Renal Function in Patients With Diabetic Nephropathy

NCT00664027
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
RTA 402 (Bardoxolone Methyl)
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Oct 21, 2026, 3:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Stepping Into Survivorship: Harnessing Behavioral Economics to Improve Quality of Life in Ovarian Cancer

NCT03364673
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Fitness Tracker, Social Incentive (Way to Health)
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 13, 2023 · Synced Oct 21, 2026, 3:14 PM EDT